CDMO executives say they are unfazed about the wave of pharma companies boosting their internal manufacturing capacity as they onshore to the US, noting this could have upsides for third-party service providers in the future. Endpoints News spoke with CEOs on the sidelines of the Convention on Pharmaceutical Ingredients confab in Frankfurt, who said that pharma companies may be overinvesting in their US footprint, which could provide acquisition opportunities for CDMOs in the future.
Read the full article: As Pharma Pour Billions in US Manufacturing, CDMOs See Future Opportunities //
Source: https://endpoints.news/as-pharma-pour-billions-in-us-manufacturing-cdmos-see-future-opportunities/